{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:17:33Z","timestamp":1757618253057,"version":"3.44.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s43440-025-00746-1","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T23:40:58Z","timestamp":1749426058000},"page":"1040-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling hidden risks: pharmacogenetic insights from a cross-sectional study of statin therapy in the Indian population"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-9581","authenticated-orcid":false,"given":"Shaik Mohammad","family":"Naushad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palani Kumar","family":"Palanichamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadeesh Babu","family":"Sreemanthula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadam Reddy","family":"Kanaka Durga Devi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palakonda","family":"Gopi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tajamul","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay Kumar","family":"Kutala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"746_CR1","doi-asserted-by":"publisher","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u2013489. https:\/\/doi.org\/10.1016\/S2213-8587(23)00119-5. PMID: 37301218.","DOI":"10.1016\/S2213-8587(23)00119-5"},{"key":"746_CR2","doi-asserted-by":"publisher","unstructured":"Gupta R, Sharma M, Goyal NK, Bansal P, Lodha S, Sharma KK. Gender differences in 7 years trends in cholesterol lipoproteins and lipids in india: insights from a hospital database. Indian J Endocrinol Metab 2016 Mar-Apr;20(2):211\u20138. https:\/\/doi.org\/10.4103\/2230-8210.176362. PMID: 27042418; PMCID: PMC4792023.","DOI":"10.4103\/2230-8210.176362"},{"key":"746_CR3","doi-asserted-by":"publisher","unstructured":"Puri R, Mehta V, Duell PB, Wangnoo SK, Rastogi A, Mohan V et al. Management of diabetic dyslipidemia in indians: expert consensus statement from the lipid association of India. J Clin Lipidol. 2023 Mar-Apr;17(2):e1\u201314. Epub 2022 Nov 23. PMID: 36577628. https:\/\/doi.org\/10.1016\/j.jacl.2022.11.002","DOI":"10.1016\/j.jacl.2022.11.002"},{"key":"746_CR4","doi-asserted-by":"publisher","unstructured":"Blais JE, Wei Y, Yap KKW, Alwafi H, Ma TT, Brauer R et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44\u201351. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.016. PMID: 34091069.","DOI":"10.1016\/j.atherosclerosis.2021.05.016"},{"issue":"22","key":"746_CR5","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.3390\/jcm11226846","volume":"11","author":"A Pradhan","year":"2022","unstructured":"Pradhan A, Kuka R, Vishwakarma P, Ali W, Perrone MA, Iellamo F, et al. Lipid profile and small dense Low-Density lipoprotein in acute coronary syndrome patients: relationships to demographic, clinical, angiographic, and therapeutic variables. J Clin Med. 2022;11(22):6846. https:\/\/doi.org\/10.3390\/jcm11226846. PMID: 36431323; PMCID: PMC9697552.","journal-title":"J Clin Med"},{"key":"746_CR6","doi-asserted-by":"publisher","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB et al. Statin safety and associated adverse events: A scientific statement from the American Heart Association. ArteriosclerThrombVasc Biol. 2019;39(2):e38-e81. https:\/\/doi.org\/10.1161\/ATV.0000000000000073. Erratum in: ArteriosclerThrombVasc Biol. 2019;39(5):e158. PMID: 30580575.","DOI":"10.1161\/ATV.0000000000000073"},{"key":"746_CR7","doi-asserted-by":"publisher","unstructured":"Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018;70(Suppl3). https:\/\/doi.org\/10.1016\/j.ihj.2018.07.009. PMID: 30595243; PMCID: PMC6309567. S120-S125.","DOI":"10.1016\/j.ihj.2018.07.009"},{"key":"746_CR8","doi-asserted-by":"publisher","unstructured":"SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S et al. SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study. N Engl J Med. 2008;359(8):789\u2013\u200999. https:\/\/doi.org\/10.1056\/NEJMoa0801936. PMID: 18650507.","DOI":"10.1056\/NEJMoa0801936"},{"key":"746_CR9","doi-asserted-by":"publisher","unstructured":"Mykk\u00e4nen AJH, Tarkiainen EK, Taskinen S, Neuvonen M, Paile-Hyv\u00e4rinen M, Lilius TO et al. Genome-wide association study of atorvastatin pharmacokinetics: Associations with SLCO1B1, UGT1A3, and LPP. Clin Pharmacol Ther. 2024;115(6):1428\u20131440. https:\/\/doi.org\/10.1002\/cpt.3236. PMID: 38493369.","DOI":"10.1002\/cpt.3236"},{"key":"746_CR10","doi-asserted-by":"publisher","unstructured":"Shahrure ZM, Irshaid YM, Mustafa KN, Abujbara MA, Al Shhab M, El-Khateeb MS et al. SLCO1B1 Gene Polymorphisms (rs2306283 and rs4149056) and Statin-Induced Myopathy in Jordanian Diabetics. Curr Rev Clin Exp Pharmacol. 2021;16(3):281\u2013288. https:\/\/doi.org\/10.2174\/1574884715666200827105612. PMID: 32860365.","DOI":"10.2174\/1574884715666200827105612"},{"key":"746_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-2350-12-136","volume":"12","author":"PC Santos","year":"2011","unstructured":"Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: amerindians as a high-risk ethnic group. BMC Med Genet. 2011;12:136. https:\/\/doi.org\/10.1186\/1471-2350-12-136. PMID: 21992719; PMCID: PMC3204270.","journal-title":"BMC Med Genet"},{"key":"746_CR12","doi-asserted-by":"publisher","unstructured":"Saber-Ayad M, Manzoor S, El-Serafi A, Mahmoud I, Abusnana S, Sulaiman N. Statin-induced myopathy SLCO1B1 521T\u2009>\u2009C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population. Diabetes Res Clin Pract. 2018;139:272\u2013277. https:\/\/doi.org\/10.1016\/j.diabres.2018.03.014. PMID: 29534995.","DOI":"10.1016\/j.diabres.2018.03.014"},{"key":"746_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203","author":"A Stewart","year":"2013","unstructured":"Stewart A. SLCO1B1 polymorphisms and Statin-Induced myopathy. PLoS Curr. 2013. https:\/\/doi.org\/10.1371\/currents.eogt.d21e7f0c58463571bb0d9d3a19b82203. PMID: 24459608; PMCID: PMC3871416.","journal-title":"PLoS Curr"},{"key":"746_CR14","doi-asserted-by":"publisher","unstructured":"Turongkaravee S, Jittikoon J, Lukkunaprasit T, Sangroongruangsri S, Chaikledkaew U, Thakkinstian A. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 2021;21(3):296\u2013307. Epub 2021 Feb 19. PMID: 33608664; PMCID: PMC8159730. https:\/\/doi.org\/10.1038\/s41397-021-00208-w","DOI":"10.1038\/s41397-021-00208-w"},{"issue":"6","key":"746_CR15","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/cpt.1557","volume":"106","author":"DF Carr","year":"2019","unstructured":"Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, et al. Genomewide association study of Statin-Induced myopathy in patients recruited using the UK clinical practice research datalink. Clin Pharmacol Ther. 2019;106(6):1353\u201361. https:\/\/doi.org\/10.1002\/cpt.1557. Epub 2019 Jul 31. PMID: 31220337; PMCID: PMC6896237.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"746_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00228-021-03233-7","volume":"78","author":"I Mer\u0107ep","year":"2022","unstructured":"Mer\u0107ep I, Radman I, Trkulja V, Bo\u017eina T, \u0160imi\u010devi\u0107 L, Budimir E, et al. Loss of function polymorphisms in SLCO1B1 (c.521T\u2009>\u2009C, rs4149056) and ABCG2 (c.421C\u2009>\u2009A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Eur J Clin Pharmacol. 2022;78(2):227\u201336. https:\/\/doi.org\/10.1007\/s00228-021-03233-7. Epub 2021 Oct 19. PMID: 34668025.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"746_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/cpt.973","volume":"104","author":"CC McLean","year":"2018","unstructured":"McLean CC, Teft WA, Morse BL, Gryn SE, Hegele RA, Kim RB. Food effect on Rosuvastatin disposition and Low-Density lipoprotein cholesterol. Clin Pharmacol Ther. 2018;104(3):525\u201333. https:\/\/doi.org\/10.1002\/cpt.973. Epub 2018 Jan 8. PMID: 29218707.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"746_CR18","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","volume":"6","author":"MK DeGorter","year":"2013","unstructured":"DeGorter MK, Tirona RG, Schwarz UI, Choi YH, Dresser GK, et al. Clinical and Pharmacogenetic predictors of Circulating Atorvastatin and Rosuvastatin concentrations in routine clinical care. Circ Cardiovasc Genet. 2013;6(4):400\u20138. https:\/\/doi.org\/10.1161\/CIRCGENETICS.113.000099. Epub 2013 Jul 22. PMID: 23876492; PMCID: PMC3922121.","journal-title":"Circ Cardiovasc Genet"},{"key":"746_CR19","doi-asserted-by":"publisher","first-page":"118624","DOI":"10.1016\/j.atherosclerosis.2024.118624","volume":"400","author":"A Gougeon","year":"2025","unstructured":"Gougeon A, Aribi I, Guernouche S, Lega JC, Wright JM, Verstuyft C, Lajoinie A, Gueyffier F, Grenet G. Publication bias in pharmacogenetics of statin-associated muscle symptoms: A meta-epidemiological study. Atherosclerosis. 2025;400:118624. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.118624. Epub 2024 Oct 18. PMID: 39488449.","journal-title":"Atherosclerosis"},{"issue":"5","key":"746_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/bioinformatics\/btx699","volume":"34","author":"BS Pedersen","year":"2018","unstructured":"Pedersen BS, Quinlan AR. Mosdepth: quick coverage calculation for genomes and exomes. Bioinformatics. 2018;34(5):867\u20138. https:\/\/doi.org\/10.1093\/bioinformatics\/btx699. PMID: 29096012; PMCID: PMC6030888.","journal-title":"Bioinformatics"},{"issue":"5","key":"746_CR21","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007\u201321. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"746_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.gene.2014.05.047","volume":"547","author":"S D\u2019Silva","year":"2014","unstructured":"D\u2019Silva S, Colah RB, Ghosh K, Mukherjee MB. Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates. Gene. 2014;547(1):18\u201322. https:\/\/doi.org\/10.1016\/j.gene.2014.05.047. Epub 2014 May 24. PMID: 24865931.","journal-title":"Gene"},{"key":"746_CR23","doi-asserted-by":"publisher","unstructured":"Kadam P, Ashavaid TF, Ponde CK, Rajani RM. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016;41(3):329\u2013\u200933. https:\/\/doi.org\/10.1111\/jcpt.12369. Epub 2016 Mar 2. PMID: 2693274.","DOI":"10.1111\/jcpt.12369"},{"key":"746_CR24","doi-asserted-by":"crossref","unstructured":"Jada SR, Xiaochen S, Yan LY, Xiaoqiang X, Lal S, Zhou SF, Ooi LL, Chowbay B. Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur J Clin Pharmacol. 2007;63(6):555\u2013\u200963. doi: 10.1007\/s00228-007-0285-5. Epub 2007 Apr 6. Erratum in: Eur J Clin Pharmacol. 2007;63(8):813-4. PMID: 17415554.","DOI":"10.1007\/s00228-007-0336-y"},{"key":"746_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fgene.2017.00167","volume":"8","author":"B Chen","year":"2017","unstructured":"Chen B, Cole JW, Grond-Ginsbach C. Departure from hardy Weinberg equilibrium and genotyping error. Front Genet. 2017;8:167. https:\/\/doi.org\/10.3389\/fgene.2017.00167. PMID: 29163635; PMCID: PMC5671567.","journal-title":"Front Genet"},{"key":"746_CR26","doi-asserted-by":"publisher","unstructured":"Manoj K, Jain N, Madhu SV. Myopathy in patients taking atorvastatin: A pilot study. Indian J Endocrinol Metab. 2017 Jul-Aug;21(4):504\u20139. https:\/\/doi.org\/10.4103\/ijem.IJEM_79_17. PMID: 28670530; PMCID: PMC5477434.","DOI":"10.4103\/ijem.IJEM_79_17"},{"issue":"4","key":"746_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/00015385.2017.1406884","volume":"73","author":"R Mulchandani","year":"2018","unstructured":"Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK. Statin related adverse effects and patient education: a study from resource limited settings. Acta Cardiol. 2018;73(4):393\u2013401. Epub 2017 Nov 27. PMID: 29179650.","journal-title":"Acta Cardiol"},{"issue":"Suppl 3","key":"746_CR28","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.ihj.2018.01.034","volume":"70","author":"D Agrawal","year":"2018","unstructured":"Agrawal D, Manchanda SC, Sawhney JPS, Kandpal B, Jain R, Mehta A, et al. To study the effect of high dose Atorvastatin 40\u00a0mg versus 80\u00a0mg in patients with dyslipidemia. Indian Heart J. 2018;70(Suppl 3):S8\u201312. https:\/\/doi.org\/10.1016\/j.ihj.2018.01.034. Epub 2018 Jan 31. PMID: 30595326; PMCID: PMC6310693.","journal-title":"Indian Heart J"},{"issue":"12","key":"746_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/pgs-2022-0044","volume":"23","author":"G Bharath","year":"2022","unstructured":"Bharath G, Vishnuprabu DP, Preethi L, Nagappan AS, DhianeshwaranIsravanya RT, Bhaskar LV, et al. SLCO1B1 and ABCB1 variants synergistically influence the Atorvastatin treatment response in South Indian coronary artery disease patients. Pharmacogenomics. 2022;23(12):683\u201394. https:\/\/doi.org\/10.2217\/pgs-2022-0044. Epub 2022 Aug 15. PMID: 35968761.","journal-title":"Pharmacogenomics"},{"issue":"3","key":"746_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jcpt.12369","volume":"41","author":"P Kadam","year":"2016","unstructured":"Kadam P, Ashavaid TF, Ponde CK, Rajani RM. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016;41(3):329\u201333. https:\/\/doi.org\/10.1111\/jcpt.12369. Epub 2016 Mar 2. PMID: 26932749.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"746_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0971-6866.142896","volume":"20","author":"L Mahadevan","year":"2014","unstructured":"Mahadevan L, Yesudas A, Sajesh PK, Revu S, Kumar P, Santhosh D, et al. Prevalence of genetic variants associated with cardiovascular disease risk and drug response in the Southern Indian population of Kerala. Indian J Hum Genet. 2014;20(2):175\u201384. https:\/\/doi.org\/10.4103\/0971-6866.142896. PMID: 25400347; PMCID: PMC4228570.","journal-title":"Indian J Hum Genet"},{"key":"746_CR32","doi-asserted-by":"publisher","unstructured":"Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics. 2023;24(7):381\u2013398. https:\/\/doi.org\/10.2217\/pgs-2023-0043. Epub 2023 May 24. PMID: 37222158; PMCID: PMC10242434.","DOI":"10.2217\/pgs-2023-0043"},{"key":"746_CR33","doi-asserted-by":"publisher","unstructured":"Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W et al. SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. OMICS. 2016;20(9):538\u2013\u200945. https:\/\/doi.org\/10.1089\/omi.2016.0119. PMID: 27631193.","DOI":"10.1089\/omi.2016.0119"},{"issue":"7","key":"746_CR34","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/pharmaceutics14071491","volume":"14","author":"JW Park","year":"2022","unstructured":"Park JW, Kim JM, Lee HY, Noh J, Kim KA, Park JY. CYP3A5*3 and SLCO1B1 c.521T\u2009>\u2009C polymorphisms influence the pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin. Pharmaceutics. 2022;14(7):1491. https:\/\/doi.org\/10.3390\/pharmaceutics14071491. PMID: 35890386; PMCID: PMC9323915.","journal-title":"Pharmaceutics"},{"key":"746_CR35","doi-asserted-by":"publisher","unstructured":"Wang Y, Tian Y, Lv P, Chen L, Luo W, Jing X et al. The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people. Pharmazie. 2017;72(6):365\u2013368. https:\/\/doi.org\/10.1691\/ph.2017.6944. PMID: 29442027.","DOI":"10.1691\/ph.2017.6944"},{"issue":"1","key":"746_CR36","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bcp.15485","volume":"89","author":"M Lehtisalo","year":"2023","unstructured":"Lehtisalo M, Taskinen S, Tarkiainen EK, Neuvonen M, Viinam\u00e4ki J, Paile-Hyv\u00e4rinen M, et al. A comprehensive Pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in Rosuvastatin pharmacokinetics. Br J Clin Pharmacol. 2023;89(1):242\u201352. https:\/\/doi.org\/10.1111\/bcp.15485. Epub 2022 Aug 22. PMID: 35942816; PMCID: PMC10087178.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"746_CR37","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","volume":"82","author":"MK Pasanen","year":"2007","unstructured":"Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of Atorvastatin and Rosuvastatin. Clin Pharmacol Ther. 2007;82(6):726\u201333. https:\/\/doi.org\/10.1038\/sj.clpt.6100220. Epub 2007 May 2. PMID: 17473846.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"746_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/FPC.0000000000000490","volume":"33","author":"HH Nguyen","year":"2023","unstructured":"Nguyen HH, Nguyen CTT, Mai TNP, Huong PT. Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis. Pharmacogenet Genomics. 2023;33(4):65\u201378. Epub 2023 Mar 6. PMID: 37098851.","journal-title":"Pharmacogenet Genomics"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00746-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00746-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:39:46Z","timestamp":1757187586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00746-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00746-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"type":"print","value":"1734-1140"},{"type":"electronic","value":"2299-5684"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Ethical Committee of Nizam\u2019s Institute of Medical Sciences (NIMS), Hyderabad (EC\/NIMS\/1578\/2015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all the study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}